论文部分内容阅读
肝纤维化是指肝内结缔组织异常增生,是慢性乙型肝炎进展为肝硬化的必经阶段,其发生、发展是影响慢性乙型肝炎预后的重要因素。因而延缓或逆转肝纤维化发展对改善预后有着十分重要的作用。作者应用恩替卡韦联合安络化纤丸治疗慢性乙型肝炎肝纤维化,取得了良好的效果,现报道如下。1资料与方法1.1一般资料2011-10/2015-12月选取门诊或住院慢性乙型肝炎肝纤维化患者共70例,所有病例的诊断均符合2015
Hepatic fibrosis refers to the abnormal proliferation of connective tissue in the liver. Hepatitis B is the necessary stage of progression of chronic hepatitis B to cirrhosis. The occurrence and development of chronic hepatitis B is an important factor affecting the prognosis of chronic hepatitis B. Thus delaying or reversing the development of liver fibrosis to improve the prognosis has a very important role. The application of entecavir joint security capsule treatment of chronic hepatitis B liver fibrosis, and achieved good results, are reported below. 1 Materials and Methods 1.1 General Information 2011 - October 2015 - December selected outpatient or hospitalized patients with chronic hepatitis B liver fibrosis, a total of 70 cases, all cases of diagnosis are in line with 2015